Skip to main content
SpringerLink
Log in

A Group-Comparative, Randomized, Double-Blind Comparison of the Efficacy and Efficiency of Two Fixed Daily Dose Regimens (100- and 200-IU) of Recombinant Follicle Stimulating Hormone (rFSH, Puregon®) in Asian Women Undergoing Ovarian Stimulation for IVF/ICSI

  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose : To compare the efficacy, efficacy and safety of a fixed daily dose of recombinant FSH (Puregon®) of a 100- and 200-IU regimen in Asian women undergoing ovarian stimulation for IVF/ICSI.

Methods : This was a prospective, randomized, double-blind, multicenter (n = 9) study. Prior to the start of rFSH, all women were pretreated with a gonadotropin releasing hormone agonist (GnRH-a) for pituitary downregulation.

Results : A total of 330 women were treated with rFSH: 163 subjects with 100 IU and 167 subjects with . In the 200 IU treatment group, significantly more oocytes were retrieved compared to the 100 IU group (9.6 vs. 5.0 oocytes, p < 0.001). The total dose rFSH needed to develop at least three follicles with a diameter of ≥17 mm was significantly lower in the 100 IU treatment group (1194 vs. 2034 IU, p < 0.001). Although more cycle cancellations were seen in the 100 IU group (24 vs. 13%), the ongoing pregnancy rate per started cycle was comparable between both groups (16.6% in the 100 IU group vs. 15.0% in the 200 IU group).

Conclusions : The use of a 100 IU fixed dose is less effective in terms of the number of oocytes retrieved and the higher cancellation rate, but more efficient as indicated by a lower total recombinant FSH dose needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Out HJ, Mannaerts BMJL, Driessen SG, Coelingh Bennink HJ: A prospective, randomized, assessor-blind, multicenter study comparing recombinant follicle-stimulating hormone (Puregon vs Metrodin) in in-vitro fertilization. Hum Reprod 1995;10:2534-2540

    Google Scholar 

  2. Devroey P, Tournaye H, van Steirteghem A, Hendrix P, Out HJ: The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Hum Reprod 1998;13:565-566

    Google Scholar 

  3. Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, Rodriguez-Escudero FJ, Garcia-Velasco JA, Pellicer A: A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999;14:622-627

    Google Scholar 

  4. Out HJ, David I, Ron-El R, Friedler S, Shalev E, Geslevich J, Dor J, Shulman A, Ben-Rafael Z, Fisch B, Dirnfeld M: A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod 2001;16:1104-1109

    Google Scholar 

  5. CPMP Working Party on Efficacy of Medicinal Products: Good Clinical Practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990;67: 361-372

    Google Scholar 

  6. Cochran WG: The combination of estimates from different experiments. Biometrics 1954;10:101-129

    Google Scholar 

  7. Cochran WG: Some methods for strengthening the common tests. Biometrics 1954;10:417-451

    Google Scholar 

  8. Land JA, Yarmolinskaya MI, Dumoulin JCM, Evers JLH: High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996;65:961-965

    Google Scholar 

  9. van Hooff MHA, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA: Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: A randomized study. Hum Reprod 1993;8:369-373

    Google Scholar 

  10. Jones HW Jr, Out HJ, Hoomans EHM, Driessen SGAJ, Coelingh Bennink HJT: Cryopreservation: the practicalities of evaluation. Hum Reprod 1997;12:1522-1524

    Google Scholar 

  11. Out HJ, Driessen SGAJ, Mannaerts BMJL, Coelingh Bennink HJT: Recombinant follicle stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil Steril 1997;68:138-142

    Google Scholar 

  12. Ubaldi F, Camus M, Smitz J, Coelingh Bennink H, van Steirteghem A, Devroey P: Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH. Fertil Steril 1996;66:275-280

    Google Scholar 

  13. Out HJ, Braat DDM, Lintsen BME, Gurgan T, Bukulmez O, Gokmen O, Keles G, Caballero P, Gonzalez JM, Fabregues F, Balasch J, Roulier R: Increasing the daily dose of recombinant follicle stimulating hormone Puregon does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod 2000;15:29-35

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Organon Nederland bv, PO Box 500, 5340 AM, Oss, The Netherlands

    Eric H. M. Hoomans

  2. NV Organon, PO Box 20, 5340 BH, Oss, The Netherlands

    Bernard B. Mulder

Authors
  1. Asian Puregon Study Group
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric H. M. Hoomans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernard B. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric H. M. Hoomans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Asian Puregon Study Group, Hoomans, E.H.M. & Mulder, B.B. A Group-Comparative, Randomized, Double-Blind Comparison of the Efficacy and Efficiency of Two Fixed Daily Dose Regimens (100- and 200-IU) of Recombinant Follicle Stimulating Hormone (rFSH, Puregon®) in Asian Women Undergoing Ovarian Stimulation for IVF/ICSI. J Assist Reprod Genet 19, 470–476 (2002). https://doi.org/10.1023/A:1020358419073

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020358419073

Search

Navigation